Claims for Patent: 10,646,495

Summary for Patent: 10,646,495

Title:	Testosterone ester triglyceride formulations
Abstract:	Testosterone ester triglyceride formulations, optionally further including adducts. Methods of in-situ control of the manufacture or formation of such adducts are also described.
Inventor(s):	Ong; Shaowei (Ewing, NJ)
Assignee:	Antares Pharma, Inc. (Ewing, NJ)
Application Number:	16/117,963
Patent Claims:	1. A testosterone ester adduct of Formula 3: ##STR00030## wherein: R.sub.1 is an alkyl or alkenyl substituent which can be the same or different at each independent occurrence; R.sub.5 is an acyl group corresponding to an unsaturated fatty acid; G is a glycerol, monoglyceride, or diglyceride residue; n is 1, 2, or 3; and the testosterone residue is connected to an allylic or doubly allylic carbon of R.sub.5. 2. The testosterone ester adduct of claim 1, wherein R.sub.1 is selected at each independent occurrence from the group consisting of propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, cyclopentylethyl and unsaturated analogs thereof. 3. The testosterone ester adduct of claim 1, having any one of Formulas 4-11: ##STR00031## ##STR00032## ##STR00033## wherein each one of R.sub.6 and R.sub.7 is independently an acyl group corresponding to a fatty acid selected from the group consisting of linoleic acid, oleic acid, palmitic acid, ricinoleic acid, linolenic acid, and stearic acid. 4. A pharmaceutical formulation for parenteral administration comprising a testosterone ester of Formula 1, a pharmaceutically acceptable carrier comprising a triglyceride of Formula 2, and a testosterone ester adduct of Formula 3 at a concentration of between 0.005 mg/ml and 25 mg/ml, ##STR00034## ##STR00035## wherein: R.sub.1 is at each independent occurrence an alkyl or alkenyl substituent; each of R.sub.2, R.sub.3, and R.sub.4 is an acyl group corresponding to a fatty acid selected from the group consisting of linoleic acid, oleic acid, palmitic acid, ricinoleic acid, linolenic acid, and stearic acid; R.sub.5 is an acyl group corresponding to an unsaturated fatty acid; G is a glycerol, monoglyceride, or diglyceride residue; n is 1, 2, or 3; and the testosterone residue in Formula 3 is connected to an allylic or doubly allylic carbon of R.sub.5. 5. The pharmaceutical formulation of claim 4, wherein the testosterone ester is testosterone enanthate, testosterone cipionate, testosterone propionate, or testosterone undecanoate. 6. The pharmaceutical formulation of claim 4 further comprising an antioxidant, wherein the testosterone ester is testosterone enanthate, the triglyceride is selected from the group consisting of LLL, OLL, OOL, OOO, PLL, POL, POO, and SOL, and the pharmaceutically acceptable carrier comprises a vegetable oil. 7. The pharmaceutical formulation of claim 6, wherein the antioxidant is selected from the group consisting of butylated hydroxy toluene (BHT), tocopherol, butylated hydroxy anisole (BHA), ascorbyl palmitate, ascorbic acid and salts thereof, vitamin E, niacinamide, methionine, monothioglycerol, sodium bisulfite, cysteine, dithionite sodium, gentisic acid, and glutamate monosodium. 8. The pharmaceutical formulation of claim 6, wherein the pharmaceutically acceptable carrier comprises sesame oil, the antioxidant is BHT, and the testosterone ester adduct has any one of Formulas 4-9: ##STR00036## ##STR00037## wherein R.sub.1 is hexyl. 9. The pharmaceutical formulation of claim 6, wherein the pharmaceutically acceptable carrier comprises sesame oil, the antioxidant is BHT, and the testosterone ester adduct has Formula 10 or Formula 11: ##STR00038## 10. The pharmaceutical formulation of claim 6, wherein the pharmaceutically acceptable carrier comprises sesame oil, the antioxidant is BHT, and the testosterone ester adduct has Formula 11: ##STR00039## 11. The pharmaceutical formulation of claim 6, wherein the concentration of testosterone enanthate ranges from 50 mg/mL to 200 mg/mL. 12. The pharmaceutical formulation of claim 6, wherein the concentration of antioxidant ranges from 0.01% to 0.1%. 13. The pharmaceutical formulation of claim 6, wherein the concentration of antioxidant ranges from 0.1 mg/mL to 1 mg/mL. 14. The pharmaceutical formulation of claim 6, wherein the vegetable oil is sesame oil.